For MS mice treated with ellagic acid, both myelin regeneration ability and movement function were improved, suggesting that SIRT3 may slow down MS progression by enhancing mitochondrial function and antioxidant capacity (Khodaei et al., 2019). This evidence concerns the gene SIRT3 and myeloid sarcoma.